Radiation boosts immunotherapy in Hard-to-Treat cancers?

NCT ID NCT07269080

Recruiting now Disease control Sponsor: University of Illinois at Chicago Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tests whether giving precise, high-dose radiation to all visible tumors (up to 10) can improve the effectiveness of immunotherapy in people with advanced solid tumors that have spread. About 28 adults with 3-10 metastases will receive radiation over 3 weeks while continuing their immunotherapy. The main goal is to see if this combination leads to a significant drop in tumor DNA in the blood at 8 weeks, which could signal better cancer control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ablative radiation therapy
What this could lead to: If successful, this could show that adding targeted radiation to immunotherapy helps control metastatic cancer better than immunotherapy alone.
What could go wrong: This is a very early phase 1 pilot with only 28 participants. It may not lead to a proven treatment, and radiation can cause side effects like fatigue or tissue damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR METASTATIC CANCER

Contacts and locations

Locations

University of Illinois at Chicago
RECRUITING

Chicago, Illinois, 60612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.